Eurofins Scientific to acquire Tata's Advinus Therapeutics

Eurofins Scientific to acquire Tata's Advinus Therapeutics
Advinus is a leading preclinical contract research company. Image Source: Advinus Therapeutics company website
By IANS
Updated: Fri, Jul 21, 2017
08:37 am
IANS
RELATED NEWS
TCS shares decline nearly 3% post Q3 earnings TCS shares decline nearly 3% post Q3 earnings
Jet Airways is in active discussions with various investors: CEO Vinay Dube Jet Airways is in active discussions with various investors: CEO Vinay Dube
PM Modi boards crisis hit Jet Airways flight, prods Tata group to save Naresh Goyal airline PM Modi boards crisis hit Jet Airways flight, prods Tata group to save Naresh Goyal airline
Exclusive! Tata, Jet Airways merger: Deal announcement may be tomorrow Exclusive! Tata, Jet Airways merger: Deal announcement may be tomorrow
Cyrus Mistry vs Tata group: An RTI reply sheds light on this surprising tun of events Cyrus Mistry vs Tata group: An RTI reply sheds light on this surprising tun of events

Tata Industries on Thursday said that laboratory testing major Eurofins Scientific will acquire its preclinical contract research company Advinus Therapeutics.

"Tata Sons, Tata Industries and Rallis India announced today that they, along with individual shareholders of Advinus Therapeutics (Advinus), have signed a definitive agreement with Eurofins Scientific (Eurofins) for Eurofins to acquire Advinus," the company said in a statement.

"The transaction is expected to close in the next several weeks, subject to the fulfilment of customary closing conditions. Advinus` expertise complements Eurofins contract research, development and manufacturing (CDMO) capabilities."

According to the statement, Advinus is a leading preclinical contract research company.

"With over 10 years of GLP compliance and certification, Advinus serves diverse industries such as Biotech, Pharmaceuticals, Biologics, Agrochemicals, Nutraceuticals and Cosmetics," the statement said.

"Advinus has submitted over 50 end-to-end investigational new drug applications (INDs) to global regulators such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency in the UK (MHRA) and Health Canada among others."